DaVita Inc. reported financial results for the quarter ended June 30, 2026, with consolidated revenues of $3.554 billion and diluted earnings per share of $4.02. Operating income reached $579 million, while operating cash flow was $490 million and free cash flow stood at $256 million. The company incurred a new Term Loan B-2 tranche totaling $500 million to repay its revolving line of credit and added remaining proceeds to the balance sheet. Additionally, DaVita repurchased 2.2 million shares for $348 million at an average price of $154.95 per share. The company operates in the healthcare industry, providing outpatient dialysis services and integrated kidney care.

DaVita Inc. entered into a Ninth Amendment to its Credit Agreement, providing for an incremental $500 million borrowing under its senior secured term loan "B" facility. Additionally, the company held its 2026 Annual Meeting of Stockholders, where directors were elected, KPMG LLP was ratified as the independent auditor, and executive compensation was approved on an advisory basis.

DaVita Inc. issued a press release on May 5, 2026, announcing its financial results for the quarter ended March 31, 2026. The specific financial figures for the period are contained in the accompanying press release exhibit rather than the body of the 8-K.

DaVita Inc. issued a press release on February 2, 2026, announcing its financial results for the quarter ended December 31, 2025. The specific financial details are contained in the press release furnished as Exhibit 99.1.

DaVita Inc. entered into an amendment to its credit agreement to establish a new $2 billion five-year secured term loan A facility and a $1.5 billion five-year secured revolving credit facility. The company intends to use the proceeds to refinance existing debt maturing in April 2028 and to fund working capital and general corporate purposes, including potential acquisitions and stock repurchases.

DaVita Inc. issued a press release on October 29, 2025, announcing its financial results for the quarter ended September 30, 2025. No specific financial figures were disclosed within the text of this 8-K filing.